Cantabio in the News

World Economic Forum: Top 10 Emerging Technologies 2019

World Economic Forum: Top 10 Emerging Technologies 2019

Cantabio was highlighted in this year’s World Economic Forum report titled “Top 10 Emerging Technologies 2019” as one of the top 10 emerging world-changing technologies for 2019. The report highlights technologies that are "disruptive, attractive to investors and researchers, and expected to have achieved considerable scale within five years”.

Cantabio was described as one of few leading companies in the world capable of therapeutically targeting intrinsically disordered proteins, a special class of promising drug targets for Alzheimer’s and cancer. The report identified Cantabio’s particular ability to target these types of proteins, previously considered by the pharmaceutical industry as impossible to target, for the development of promising new drugs in the areas of neurodegeneration and cancer.

(Each year at the World Economic Forum (WEF), an international Steering Committee of leading technology experts engage in an intense process to identify the Top 10 Emerging Technologies, technologies that alter the status quo of doing things and have the potential to provide major benefits to societies and economies.)

 

Source and full details from: https://www.weforum.org/reports/top-10-emerging-technologies-2019

Cantabio in Scientific American

Cantabio in Scientific American

Scientific American highlights Cantabio as one of the few companies capable of therapeutic targeting intrinsically disordered proteins, a special class of promising drug targets for Alzheimer’s and cancer. Scientific American highlights Cantabio as one of the few companies capable of therapeutic targeting intrinsically disordered proteins, a special class of promising drug targets for Alzheimer’s and cancer.
The Tao of Tau & Picking apart PD

The Tao of Tau & Picking apart PD

DD News Pharma Biotech and Life Science featured Cantabio's recent peer reviewed publication in ACS Chemical Neuroscience on the structural basis for the suitability of Tau as a drug target, as well as reporting on Cantabio's recently announced positive in vivo efficacy in mammalian Parkinson's disease model of a candidate from its DJ-1 targeting small molecule program
Drugging the Disorderome; Strategies for targeting intrinsically disordered proteins

Drugging the Disorderome; Strategies for targeting intrinsically disordered proteins

Cantabio's therapeutic program on Alzheimer’s and Parkinson's disease was featured as part of an article titled "Drugging the Disorderome" in the October 2017 issue of The Scientist magazine.  The article reviewed the potential for developing therapeutics for historically difficult to target intrinsically disordered proteins, the new techniques that can allow the screening for drug candidates to target them and highlighted Cantabio's expertise in this area.

Chaperoning the DJ

Chaperoning the DJ

Cover Story by Biocentury Innovations, describing how Cantabio is using an alternative approach, enhancing the function of the DJ-1 protein, rather than the more common dopamine compensation strategy. This means developing a disease-modifying therapy instead of treating only the disease's symptoms. Mentioning also our pharmacological chaperone approach in Alzheimer's targeting B-amyloid and tau.